🟢 Chemours is trading 6% up in pre-market after outlining Pathway to Thrive strategy

Chemours is trading 6.43% up now at $16.01 after releasing a September 9 investor presentation outlining its Pathway to Thrive strategy and long-term target of more than $1 billion in adjusted EBITDA.

• The plan highlights operational improvements, financial targets and growth opportunities tied to AI infrastructure and data centers.
• Shares are rising despite modestly weaker major U.S. equity futures.